Published in Proc Natl Acad Sci U S A on October 01, 2003
The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol (2010) 3.32
100 years and counting: prospects for defeating Alzheimer's disease. Science (2006) 3.24
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature (2010) 2.80
Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol (2010) 2.12
5-lipoxygenase as an endogenous modulator of amyloid β formation in vivo. Ann Neurol (2010) 2.06
Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb Perspect Med (2012) 2.02
When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep (2007) 1.81
Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov (2010) 1.64
Inhibition and modulation of gamma-secretase for Alzheimer's disease. Neurotherapeutics (2008) 1.55
gamma-Secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem (2005) 1.45
Berberine attenuates axonal transport impairment and axonopathy induced by Calyculin A in N2a cells. PLoS One (2014) 1.40
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress. Annu Rev Med (2013) 1.36
Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc Natl Acad Sci U S A (2009) 1.34
Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS One (2011) 1.32
Intramembrane proteolysis. Chem Rev (2009) 1.32
Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis (2010) 1.26
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
The β-secretase-derived C-terminal fragment of βAPP, C99, but not Aβ, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J Neurosci (2012) 1.11
γ-Secretase inhibitors and modulators for Alzheimer's disease. J Neurochem (2011) 1.09
Regulation of Alzheimer's disease amyloid-beta formation by casein kinase I. Proc Natl Acad Sci U S A (2007) 1.09
Gamma-secretase inhibition and modulation for Alzheimer's disease. Curr Alzheimer Res (2008) 1.09
Target deconvolution techniques in modern phenotypic profiling. Curr Opin Chem Biol (2013) 1.08
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease. Hum Mol Genet (2014) 1.03
Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin. Mol Biol Cell (2007) 0.99
Proteolytic cleavage of Notch: "HIT and RUN". Curr Mol Med (2011) 0.95
Quantification of gamma-secretase modulation differentiates inhibitor compound selectivity between two substrates Notch and amyloid precursor protein. Mol Brain (2008) 0.94
Structure, mechanism and inhibition of gamma-secretase and presenilin-like proteases. Biol Chem (2010) 0.93
Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol (2007) 0.93
Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease. Alzheimers Res Ther (2010) 0.91
Involvement of 5-lipoxygenase in the corticosteroid-dependent amyloid beta formation: in vitro and in vivo evidence. PLoS One (2011) 0.90
Chemical Biology, Molecular Mechanism and Clinical Perspective of γ-Secretase Modulators in Alzheimer's Disease. Curr Neuropharmacol (2011) 0.89
Dynamin 1 regulates amyloid generation through modulation of BACE-1. PLoS One (2012) 0.89
Discovery of notch-sparing gamma-secretase inhibitors. Curr Alzheimer Res (2010) 0.88
Purification and characterization of the human γ-secretase activating protein. Biochemistry (2012) 0.88
At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.86
Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine. BMC Med (2013) 0.85
Phenotypic analysis of images of zebrafish treated with Alzheimer's gamma-secretase inhibitors. BMC Biotechnol (2010) 0.85
Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. Mol Neurodegener (2010) 0.85
Inhibition of heme synthesis alters Amyloid Precursor Protein processing. J Neural Transm (Vienna) (2008) 0.81
Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. PLoS One (2012) 0.81
Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines. BMC Med Genomics (2012) 0.81
Selective amyloid-beta lowering agents. BMC Neurosci (2008) 0.80
The role of γ-secretase activating protein (GSAP) and imatinib in the regulation of γ-secretase activity and amyloid-β generation. J Biol Chem (2012) 0.80
The Guinea Pig as a Model for Sporadic Alzheimer's Disease (AD): The Impact of Cholesterol Intake on Expression of AD-Related Genes. PLoS One (2013) 0.79
Role of zinc metallothionein-3 (ZnMt3) in epidermal growth factor (EGF)-induced c-Abl protein activation and actin polymerization in cultured astrocytes. J Biol Chem (2011) 0.78
Comparison of pharmacological modulation of APP metabolism in primary chicken telencephalic neurons and in a human neuroglioma cell line. J Mol Neurosci (2010) 0.78
In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing gamma-secretase inhibitors. J Neurochem (2010) 0.77
Regulation of gamma-secretase activating protein by the 5Lipoxygenase: in vitro and in vivo evidence. Sci Rep (2015) 0.77
Alzheimer's disease: Selectively tuning gamma-secretase. Nature (2010) 0.77
Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage. Proc Natl Acad Sci U S A (2017) 0.75
The Achilles heel of γ-secretase: can we contain Alzheimer's disease by reducing synthesis of β-amyloid? Acta Pharmacol Sin (2010) 0.75
Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? Open Neurol J (2009) 0.75
Unlocking truths of γ-secretase in Alzheimer's disease: what is the translational potential? Future Neurol (2015) 0.75
gamma-secretase activating protein is a therapeutic target for alzheimer 's disease: a path-breaking discovery finally paving way towards therapeutic intervention. Ann Neurosci (2011) 0.75
Original Research: Featured Article: Imatinib mesylate (Gleevec) inhibits Notch and c-Myc signaling: Five-day treatment permanently rescues mammary development. Exp Biol Med (Maywood) (2016) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature (1998) 10.58
A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature (2001) 7.35
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 5.30
GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Signal transduction by activated mNotch: importance of proteolytic processing and its regulation by the extracellular domain. Proc Natl Acad Sci U S A (1996) 4.13
A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep (2002) 3.53
A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48
Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl Acad Sci U S A (2000) 3.13
L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry (2000) 2.36
APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron (2001) 2.31
Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med (1998) 2.20
Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides. Proc Natl Acad Sci U S A (1999) 1.99
Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci U S A (1999) 1.98
The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport (1999) 1.59
Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the generation of amyloid beta-protein in endoplasmic reticulum and Golgi. Biochemistry (1998) 1.57
Involvement of the ubiquitin/proteasome system in sorting of the interleukin 2 receptor beta chain to late endocytic compartments. Mol Biol Cell (2001) 1.54
Prohormone processing in the trans-Golgi network: endoproteolytic cleavage of prosomatostatin and formation of nascent secretory vesicles in permeabilized cells. J Cell Biol (1993) 1.52
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res (1999) 1.51
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res (2002) 1.34
Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol (2002) 1.30
Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett (2002) 1.29
Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway. J Biol Chem (2003) 1.08
Use of a colorimetric microtiter (MTT) assay in determining the radiosensitivity of cells from murine solid tumors. Int J Radiat Oncol Biol Phys (1988) 1.08
Carboxyl-terminal fragments of Alzheimer beta-amyloid precursor protein accumulate in restricted and unpredicted intracellular compartments in presenilin 1-deficient cells. J Biol Chem (2000) 1.02
Direct evidence for ATP modulation of sugar transport in human erythrocyte ghosts. J Biol Chem (1986) 1.00
The use of seldi proteinchip arrays to monitor production of Alzheimer's betaamyloid in transfected cells. J Pept Sci (2000) 0.93
Emerging Alzheimer's disease therapies: inhibition of beta-secretase. Neurobiol Aging (2002) 0.90
Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. Mol Cancer Res (2003) 0.89
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. Proc Natl Acad Sci U S A (2000) 0.89
The effect of oligomycin on the respiration of tissue slices. Biochim Biophys Acta (1965) 0.88
Axonal regeneration of sensory nerves is delayed by continuous intrathecal infusion of nerve growth factor. Neuroscience (1997) 0.87
Cell-free generation of the notch1 intracellular domain (NICD) and APP-CTfgamma: evidence for distinct intramembranous "gamma-secretase" activities. Neuromolecular Med (2002) 0.83
Gamma-secretase inhibitors and Alzheimer's disease. Adv Drug Deliv Rev (2002) 0.82
Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer's disease. Pharmacotherapy (2002) 0.80
Disturbances of the blood-brain barrier without expression of amyloid precursor protein- containing neuritic clusters or neuronal loss during late stages of thiamine deficiency in guinea pigs. Dev Neurosci (1998) 0.80
Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med (2003) 12.94
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
A translational profiling approach for the molecular characterization of CNS cell types. Cell (2008) 8.69
Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell (2008) 7.74
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Dichotomous dopaminergic control of striatal synaptic plasticity. Science (2008) 5.47
Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell (2003) 5.44
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol (2003) 4.60
Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med (2007) 4.48
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
Essential role of the histone methyltransferase G9a in cocaine-induced plasticity. Science (2010) 3.97
Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A (2004) 3.87
DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol (2004) 3.84
Cocaine-induced dendritic spine formation in D1 and D2 dopamine receptor-containing medium spiny neurons in nucleus accumbens. Proc Natl Acad Sci U S A (2006) 3.68
Alterations in 5-HT1B receptor function by p11 in depression-like states. Science (2006) 3.55
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci (2003) 3.25
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Spinal axon regeneration induced by elevation of cyclic AMP. Neuron (2002) 3.09
Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci (2004) 3.05
Cocaine regulates MEF2 to control synaptic and behavioral plasticity. Neuron (2008) 3.01
Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. J Biol Chem (2004) 2.85
IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab (2012) 2.80
Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature (2010) 2.80
Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (2008) 2.79
Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature (2006) 2.77
Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis (2005) 2.70
Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS (2003) 2.69
Diverse psychotomimetics act through a common signaling pathway. Science (2003) 2.52
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med (2005) 2.43
Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A (2011) 2.37
Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc Natl Acad Sci U S A (2010) 2.36
P25-graphene composite as a high performance photocatalyst. ACS Nano (2010) 2.34
Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A (2003) 2.32
Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex. Neuron (2009) 2.26
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst (2008) 2.21
Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res (2006) 2.15
IκB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J Neurosci (2011) 2.15
Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci (2007) 2.11
A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature (2008) 2.10
Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens. Sci Transl Med (2010) 2.09
Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res (2010) 2.05
Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies. Neuron (2003) 2.04
APP processing in Alzheimer's disease. Mol Brain (2011) 2.02
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS (2002) 1.98
Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol (2002) 1.97
MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science (2013) 1.95
Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit. Proc Natl Acad Sci U S A (2007) 1.93
An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc Natl Acad Sci U S A (2007) 1.92
Involvement of DARPP-32 phosphorylation in the stimulant action of caffeine. Nature (2002) 1.91
Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem (2007) 1.91
The neurobiology of dopamine signaling. Arch Neurol (2004) 1.89
Cocaine increases dopamine release by mobilization of a synapsin-dependent reserve pool. J Neurosci (2006) 1.88
Phactrs 1-4: A family of protein phosphatase 1 and actin regulatory proteins. Proc Natl Acad Sci U S A (2004) 1.86
Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal (2009) 1.84
Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci (2002) 1.82
Three-dimensional architecture of presynaptic terminal cytomatrix. J Neurosci (2007) 1.82
Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol (2012) 1.81
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res (2007) 1.79
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One (2010) 1.78
PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. J Biol Chem (2003) 1.77
Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc Natl Acad Sci U S A (2007) 1.77
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A (2009) 1.76
Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice. Proc Natl Acad Sci U S A (2004) 1.72
Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem (2004) 1.72
Different presynaptic roles of synapsins at excitatory and inhibitory synapses. J Neurosci (2004) 1.72
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci U S A (2006) 1.71
Increased frequency of circulating follicular helper T cells in patients with rheumatoid arthritis. Clin Dev Immunol (2012) 1.70
DARPP-32 mediates the actions of multiple drugs of abuse. AAPS J (2005) 1.66
Impaired recycling of synaptic vesicles after acute perturbation of the presynaptic actin cytoskeleton. Proc Natl Acad Sci U S A (2002) 1.64
Abeta-mediated NMDA receptor endocytosis in Alzheimer's disease involves ubiquitination of the tyrosine phosphatase STEP61. J Neurosci (2010) 1.64
Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci (2008) 1.63
Role of p11 in cellular and behavioral effects of 5-HT4 receptor stimulation. J Neurosci (2009) 1.62
Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci (2002) 1.62
Presenilin 1 is required for maturation and cell surface accumulation of nicastrin. J Biol Chem (2002) 1.61
Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci U S A (2007) 1.61
Loss of sorting nexin 27 contributes to excitatory synaptic dysfunction by modulating glutamate receptor recycling in Down's syndrome. Nat Med (2013) 1.61
Molecular adaptations of striatal spiny projection neurons during levodopa-induced dyskinesia. Proc Natl Acad Sci U S A (2014) 1.59
Epidemiology of hand, foot, and mouth disease and genotype characterization of Enterovirus 71 in Jiangsu, China. J Clin Virol (2010) 1.58
Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol (2010) 1.57
The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. Neuron (2005) 1.57
L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem (2009) 1.53
Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell (2011) 1.52
Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science (2004) 1.52
Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc Natl Acad Sci U S A (2002) 1.51
Colocalization of synapsin and actin during synaptic vesicle recycling. J Cell Biol (2003) 1.50
Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metab (2011) 1.50
Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol (2003) 1.50